相似文献
1
Molecular staging of gynecological cancer: What is the future?
Best Pract Res Clin Obstet Gynaecol. 2015 Aug;29(6):776-89. doi: 10.1016/j.bpobgyn.2015.01.008. Epub 2015 Mar 4.
2
Prognostic significance of S-phase fraction as measured by DNA flow cytometry in gynecologic malignancies.
Ann N Y Acad Sci. 1993 Mar 20;677:354-63. doi: 10.1111/j.1749-6632.1993.tb38790.x.
3
Clinical implications of insulin-like growth factors through the presence of their binding proteins and receptors expressed in gynecological cancers.
Eur J Gynaecol Oncol. 2004;25(2):187-91.
4
Prospective analysis of DNA ploidy, proliferative index and epidermal growth factor receptor as prognostic factors for pretreated uterine cancer.
Oncol Rep. 2000 May-Jun;7(3):551-9. doi: 10.3892/or.7.3.551.
5
Report of the National Cancer Institute and the Eunice Kennedy Shriver National Institute of Child Health and Human Development-sponsored workshop: gynecology and women's health-benign conditions and cancer.
Am J Obstet Gynecol. 2020 Dec;223(6):796-808. doi: 10.1016/j.ajog.2020.08.049. Epub 2020 Aug 21.
6
What we could do now: molecular pathology of gynaecological cancer.
Mol Pathol. 2001 Aug;54(4):222-4. doi: 10.1136/mp.54.4.222.
7
Ploidy in gynaecological cancers.
Histopathology. 2005 Feb;46(2):121-9. doi: 10.1111/j.1365-2559.2005.02087.x.
8
Sperm protein 17 is highly expressed in endometrial and cervical cancers.
BMC Cancer. 2010 Aug 16;10:429. doi: 10.1186/1471-2407-10-429.
9
Hypermethylation of miR-203 in endometrial carcinomas.
Gynecol Oncol. 2014 May;133(2):340-5. doi: 10.1016/j.ygyno.2014.02.009. Epub 2014 Feb 14.
10
Long Non-coding RNA NEAT1 as an Emerging Biomarker in Breast and Gynecologic Cancers: a Systematic Overview.
Reprod Sci. 2021 Sep;28(9):2436-2447. doi: 10.1007/s43032-021-00481-x. Epub 2021 Feb 10.
引用本文的文献
1
Integration of machine learning and bulk sequencing revealed exosome-related gene FOSB was involved in the progression of abdominal aortic aneurysm.
Front Cell Dev Biol. 2025 May 22;13:1554972. doi: 10.3389/fcell.2025.1554972. eCollection 2025.
2
Molecular Signatures of Gynecological Cancers: Clinicians Perspective.
Indian J Surg Oncol. 2021 Apr;12(Suppl 1):103-110. doi: 10.1007/s13193-020-01271-8. Epub 2021 Feb 2.
3
Predicting high-risk endometrioid carcinomas using proteins.
Oncotarget. 2018 Apr 13;9(28):19704-19715. doi: 10.18632/oncotarget.24803.
4
The Complementary Role of Imaging and Tumor Biomarkers in Gynecological Cancers: An Update of the Literature.
Asian Pac J Cancer Prev. 2018 Feb 26;19(2):309-317. doi: 10.22034/APJCP.2018.19.2.309.
5
The Importance of Steroid Uptake and Intracrine Action in Endometrial and Ovarian Cancers.
Front Pharmacol. 2017 Jun 19;8:346. doi: 10.3389/fphar.2017.00346. eCollection 2017.
本文引用的文献
1
Safety and Antitumor Activity of Anti-PD-1 Antibody, Nivolumab, in Patients With Platinum-Resistant Ovarian Cancer.
J Clin Oncol. 2015 Dec 1;33(34):4015-22. doi: 10.1200/JCO.2015.62.3397. Epub 2015 Sep 8.
2
A phase II evaluation of nintedanib (BIBF-1120) in the treatment of recurrent or persistent endometrial cancer: an NRG Oncology/Gynecologic Oncology Group Study.
Gynecol Oncol. 2014 Dec;135(3):441-5. doi: 10.1016/j.ygyno.2014.10.001. Epub 2014 Oct 13.
3
Ovarian cancer stem cells: Can targeted therapy lead to improved progression-free survival?
World J Stem Cells. 2014 Sep 26;6(4):441-7. doi: 10.4252/wjsc.v6.i4.441.
4
HPV-negative carcinoma of the uterine cervix: a distinct type of cervical cancer with poor prognosis.
BJOG. 2015 Jan;122(1):119-27. doi: 10.1111/1471-0528.13071. Epub 2014 Sep 17.
5
Polymerase ɛ (POLE) mutations in endometrial cancer: clinical outcomes and implications for Lynch syndrome testing.
Cancer. 2015 Feb 1;121(3):386-94. doi: 10.1002/cncr.29046. Epub 2014 Sep 15.
6
Clinical significance of CTNNB1 mutation and Wnt pathway activation in endometrioid endometrial carcinoma.
J Natl Cancer Inst. 2014 Sep 10;106(9). doi: 10.1093/jnci/dju245. Print 2014 Sep.
7
The search for biomarkers to direct antiangiogenic treatment in epithelial ovarian cancer.
Gynecol Oncol. 2014 Nov;135(2):349-58. doi: 10.1016/j.ygyno.2014.08.033. Epub 2014 Aug 30.
8
Candidate biomarkers for cervical cancer treatment: Potential for clinical practice (Review).
Mol Clin Oncol. 2014 Sep;2(5):647-655. doi: 10.3892/mco.2014.324. Epub 2014 Jun 23.
9
A phase II trial of brivanib in recurrent or persistent endometrial cancer: an NRG Oncology/Gynecologic Oncology Group Study.
Gynecol Oncol. 2014 Oct;135(1):38-43. doi: 10.1016/j.ygyno.2014.07.083. Epub 2014 Jul 11.
10
Update on prognostic markers for endometrial cancer.
Womens Health (Lond). 2014 May;10(3):277-88. doi: 10.2217/whe.14.13.
Zotero 插件